Ready to take control of your blood sugar? A groundbreaking study reveals a surprising truth: consistent use of continuous glucose monitors (CGMs) can dramatically improve blood sugar control for adults with type 2 diabetes. This is a game-changer!
The research, published in JAMA Network Open, delved into electronic medical data to uncover the impact of CGM usage. The findings are compelling.
In a study of 9,258 patients, those who diligently wore their glucose monitors – at least 75% of the time – experienced the most significant improvements in their hemoglobin A1c (HbA1c) levels after just one year. HbA1c, for those unfamiliar, is a key indicator of average blood sugar levels over time.
On average, these dedicated users saw their HbA1c levels plummet by 1.52 percentage points. In contrast, those who used the device less frequently saw a much smaller reduction of only 0.63 percentage points.
But here's where it gets interesting: the most consistent users achieved rapid results, with noticeable HbA1c reductions within the first three months. While some moderate users plateaued after six months, the frequent users maintained their benefits throughout the entire year.
Dr. Irl Hirsch, an endocrinologist at UW Medicine and a corresponding author, was surprised by the advantages of full-time CGM use. He noted that while continuous monitoring has long been understood as crucial for type 1 diabetes patients, type 2 diabetes patients often only use CGMs for short periods before doctor's appointments.
The research team was also taken aback by the dramatic HbA1c drops among the consistent users compared to the control group. "This evidence suggests that wearing a glucose monitor prompts them to behave better when they see the data in real time, without taking any breaks from wearing it," Dr. Hirsch explained. "I didn’t realize that.”
And this is the part most people miss: Patients who combined consistent CGM use with GLP-1 drugs saw even greater improvements. After one year, they showed an average treatment difference of 1.13 percentage points compared to controls.
Dr. Hirsch was astounded by these results, highlighting the significant impact of continuous glucose monitoring. The authors emphasized that consistency is key: regular CGM use leads to meaningful, lasting improvements in blood sugar control, ultimately reducing the risk of long-term diabetes complications.
The researchers suggest that clinicians should review CGM use at the six-month mark to identify potential obstacles and reinforce the benefits of monitoring to sustain results, as this is when patient adherence often declines.
The study utilized data from Optum de-identified Market Clarity Data, a large U.S. database containing electronic medical records and claims information. The study included claimants between June 30, 2019, and Jan. 5, 2023, and was funded by Roche Diagnostics.
What do you think? Does this study change your perspective on CGM use? Share your thoughts and experiences in the comments below! Do you think the six-month mark is a critical point for patient support? Let's discuss!
.png)
